Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

  • Chatzikonstantinou, Thomas
  • Gimeno Vázquez, Eva
  • Puiggros Metje, Anna Maria
  • Espinet Solà, Blanca
  • Stamatopoulos, Kostas
Background: Patients with chronic lymphocytic leukemia (CLL) have a higher risk of developing other malignancies (OMs) compared to the general population. However, the impact of CLL-related risk factors and CLL-directed treatment is still unclear and represents the focus of this work. Methods: We conducted a retrospective international multicenter study to assess the incidence of OMs and detect potential risk factors in 19,705 patients with CLL, small lymphocytic lymphoma, or high-count CLL-like monoclonal B-cell lymphocytosis, diagnosed between 2000 and 2016. Data collection took place between October 2020 and March 2022. Findings: In 129,254 years of follow-up after CLL diagnosis, 3513 OMs were diagnosed (27.2 OMs/1000 person-years). The most common hematological OMs were Richter transformation, myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Non-melanoma skin (NMSC) and prostate cancers were the most common solid tumors (STs).The only predictor for MDS and AML development was treatment with fludarabine and cyclophosphamide with/without rituximab (FC ± R) (OR = 3.7; 95% CI = 2.79-4.91; p < 0.001). STs were more frequent in males and patients with unmutated immunoglobulin heavy variable genes (OR = 1.77; 95% CI = 1.49-2.11; p < 0.001/OR = 1.89; 95% CI = 1.6-2.24; p < 0.001).CLL-directed treatment was associated with non-melanoma skin and prostate cancers (OR = 1.8; 95% CI = 1.36-2.41; p < 0.001/OR = 2.11; 95% CI = 1.12-3.97; p = 0.021). In contrast, breast cancers were more frequent in untreated patients (OR = 0.17; 95% CI = 0.08-0.33; p < 0.001).Patients with CLL and an OM had inferior overall survival (OS) than those without. AML and MDS conferred the worst OS (p < 0.001). Interpretation: OMs in CLL impact on OS. Treatment for CLL increased the risk for AML/MDS, prostate cancer, and NMSC. FCR was associated with increased risk for AML/MDS. Funding: AbbVie, and EU/EFPIAInnovative Medicines Initiative Joint Undertaking HARMONY grant n° 116026., This project was supported in part by AbbVie; EU/EFPIA Innovative Medicines Initiative [2] Joint Undertaking HARMONY grant n° 116026; the Hellenic Precision Medicine Network in Oncology; MH-CZ_AZV_NU23-03-00401; MH CZ DRO (FNBr, 65269705); MH CZ DRO (FNOl, 00098892), program COOPERATIO (research area ONCO), and NPO-NUVR LX22NPO5102. Munci Yagci was provided with study materials.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Core outcome set measurement for future clinical trials in acute myeloid leukemia: the HARMONY study protocol using a multi-stakeholder consensus-based Delphi process and a final consensus meeting

  • Lang, Katharina M.
  • Harrison, Kathryn L.
  • Williamson, Paula R.
  • Huntly, Brian J. P.
  • Ossenkoppele, Gert
  • Geissler, Jan
  • Bereczky, Tamàs
  • Chevrou-Séverac, Hélène
  • Goodbody, Rory
  • Schulze-Rath, Renate
  • Bullinger, Lars
© The Author(s)., [Background]: Acute myeloid leukemia (AML) is the most common acute leukemia in adults and has an unacceptably low cure rate. In recent years, a number of new treatment strategies and compounds were developed for the treatment of AML. There were several randomized controlled clinical trials with the objective to improve patients’ management and patients’ outcome in AML. Unfortunately, these trials are not always directly comparable since they do not measure the same outcomes, and currently there are no core outcome sets that can be used to guide outcome selection and harmonization in this disease area. The HARMONY (Healthcare Alliance for Resourceful Medicine Offensive against Neoplasms in Hematology) Alliance is a public-private European network established in 2017 and currently includes 53 partners and 32 associated members from 22 countries. Amongst many other goals of the HARMONY Alliance, Work Package 2 focuses on defining outcomes that are relevant to each hematological malignancy. Accordingly, this pilot study will be performed to define a core outcome set in AML., [Methods]: The pilot study will use a three-round Delphi survey and a final consensus meeting to define a core outcome set. Participants will be recruited from different stakeholder groups, including patients, clinicians, regulators and members of the European Federation of Pharmaceutical Industries and Associations. At the pre-Delphi stage, a literature research was conducted followed by several semi-structured interviews of clinical public and private key opinion leaders. Subsequently, the preliminary outcome list was discussed in several multi-stakeholder face-to-face meetings. The Delphi survey will reduce the preliminary outcome list to essential core outcomes. After completion of the last Delphi round, a final face-to-face meeting is planned to achieve consensus about the core outcome set in AML., [Discussion]: As part of the HARMONY Alliance, the pilot Delphi aims to define a core outcome set in AML on the basis of a multi-stakeholder consensus. Such a core outcome set will help to allow consistent comparison of future clinical trials and real-world evidence research and ensures that appropriate outcomes valued by a range of stakeholders are measured within future trials., This work was funded through the Innovative Medicines Initiative 2 joint undertaking and listed under grant agreement 116026. This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the EFPIA. An additional cash grant was obtained from Bayer AG for conducting the Delphi survey development
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia

  • Ribera, Josep-Maria
  • García-Calduch, Olga
  • Ribera, Jordi
  • Montesinos, Pau
  • Cano-Ferr, Isabel
  • Martínez, Pilar
  • Esteve, Jordi
  • Esteban, Daniel
  • García-Fortes, María
  • Alonso, Natalia
  • González-Campos, José A.
  • Bermúdez, Arantxa
  • Torrent, Anna
  • Genescà, Eulàlia
  • Mercadal, Santiago
  • Martínez-López, Joaquín
  • García-Sanz, Ramón
Promising results have been shown with the combination of ponatinib and chemotherapy in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL). The PONALFIL (Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia) trial combined ponatinib (30 mg/d) with standard induction and consolidation chemotherapy followed by allogeneic hematopoietic stem cell transplant (alloHSCT) in newly diagnosed Ph+ ALL patients aged 18 to 60 years. Ponatinib was only given pre-emptively after alloHSCT. Primary end points were hematologic and molecular response before alloHSCT and event-free survival (EFS), including molecular relapse as event. Thirty patients (median age, 49 years; range, 19-59 years) entered the trial. All exhibited hematologic response, and alloHSCT was performed in 26 patients (20 in complete molecular response and 6 in major molecular response). Only 1 patient died (of graft-versus-host disease), and 5 patients exhibited molecular relapse after alloHSCT. No tyrosine kinase inhibitor was given after HSCT in 18 of 26 patients. Twenty-nine patients are alive (median follow-up, 2.1 years; range, 0.2-4.0 years), with 3-year EFS and overall survival (OS) of 70% (95% confidence interval, 51-89) and 96% (95% confidence interval, 89-100), respectively. Comparison of the PONALFIL and the ALLPh08 (Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph [BCR-ABL] Positive; same schedule, using imatinib as the tyrosine kinase inhibitor) trials by propensity score showed significant improvement in OS for patients in PONALFIL (3-year OS, 96% vs 53%; P = .002). The most frequent grade 3 to 4 adverse events were hematologic (42%), infectious (17%), and hepatic (22%), with only one vascular occlusive event. The combination of chemotherapy with ponatinib followed by alloHSCT is well tolerated, with encouraging EFS in adults with newly diagnosed Ph+ ALL. Cross-trial comparison suggests improvement vs imatinib (clinicaltrials.gov identifier #NCT02776605)., This project was supported in part by the ISCIII (PI14/01971 and PI19/01828), cofunded by ERDF/ESF, “A way to make Europe”/ “Investing in your future,” CERCA/Generalitat de Catalunya SGR 2017 288 (GRC)/“La Caixa.” This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 116026. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation and the European Federation of Pharmaceutical Industries and Associations., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells

  • García-Guerrero, Estefanía
  • Rodríguez-Lobato, Luis Gerardo
  • Sierro-Martínez, Belén
  • Danhof, Sophia
  • Bates, Stephan
  • Frenz, Silke
  • Haertle, Larissa
  • Götz, Ralph
  • Sauer, Markus
  • Rasche, Leo
  • Kortüm, K Martin
  • Pérez-Simón, José A.
  • Einsele, Hermann
  • Hudecek, Michael
  • Prommersberger, Sabrina R.
B-cell maturation antigen (BCMA) is the lead antigen for chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM). A challenge is inter- and intra-patient heterogeneity in BCMA expression on MM cells and BCMA downmodulation under therapeutic pressure. Accordingly, there is a desire to augment and sustain BCMA expression on MM cells in patients that receive BCMA-CAR T-cell therapy. We used all-trans retinoic acid (ATRA) to augment BCMA expression on MM cells and to increase the efficacy of BCMA-CAR T cells in pre-clinical models. We show that ATRA treatment leads to an increase in BCMA transcripts by quantitative reverse transcription polymerase chain reaction and an increase in BCMA protein expression by flow cytometry in MM cell lines and primary MM cells. Analyses with super-resolution microscopy confirmed increased BCMA protein expression and revealed an even distribution of non-clustered BCMA molecules on the MM cell membrane after ATRA treatment. The enhanced BCMA expression on MM cells after ATRA treatment led to enhanced cytolysis, cytokine secretion and proliferation of BCMA-CAR T cells in vitro, and increased efficacy of BCMA-CAR T-cell therapy in a murine xenograft model of MM in vivo (NSG/MM.1S). Combination treatment of MM cells with ATRA and the γ- secretase inhibitor crenigacestat further enhanced BCMA expression and the efficacy of BCMA-CAR T-cell therapy in vitro and in vivo. Taken together, the data show that ATRA treatment leads to enhanced BCMA expression on MM cells and consecutively, enhanced reactivity of BCMA-CAR T cells. The data support the clinical evaluation of ATRA in combination with BCMA-CAR T-cell therapy and potentially, other BCMA-directed immunotherapies., EGG has been supported by Instituto de Salud Carlos III (PFIS - FI12/00189 and PI20/01792). LGRL has been a BITRECS fellow and has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No 754550 and from the “La Caixa” Foundation. SD has been supported by the IZKF Würzburg (Interdisziplinäres Zentrum für Klinische Forschung) and is a fellow of the Clinician Scientist Program of the Else-Kröner Forschungskolleg. The authors have been supported by the patient advocacy group 'Hilfe im Kampf gegen den Krebs e.V.', Würzburg, Germany and 'Forschung hilft' - Stiftung zur Förderung der Krebsforschung an der Universität Würzburg. Further, the authors have been supported by the European Union’s Horizon 2020 research and innovation program under grant agreements No 733297 (EURE-CART to MH, HE and SRP) and No 754658 (CARAMBA to MH, SD, SRP and HE), the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG, project number 324392634, TRR 221, subproject A03 to MH and HE), the Bavarian Center for Cancer Research (Bayerisches Zentrum für Krebsforschung, BZKF to MH, HE and SRP) and the Stifterverband für die Deutsche Wissenschaft e.V. (to KMK and MH). MS, MH and HE acknowledge funding by the German Ministry for Science and Education (BMBF, Bundesministerium für Bildung und Forschung, grant #13N15986). Further, the authors have been supported by the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116026 (T2EVOLVE). This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and EFPIA., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

  • Chatzikonstantinou, Thomas
  • Scarfò, Lydia
  • Karakatsoulis, Georgios
  • Minga, Eva
  • Chamou, Dimitra
  • Iacoboni, Gloria
  • Kotaskova, Jana
  • Demosthenous, Christos
  • Smolej, Lukas
  • Mulligan, Stephen
  • Alcoceba, Miguel
  • Calleja, Anne
  • Medina, Angeles
  • Khan, Mehreen Ali
  • Cassin, Ramona
  • Chatzileontiadou, Sofía
  • Collado, Rosa
  • Christian, Amy
  • Davis, Zadie
  • Dimou, María
  • Donaldson, David
  • Kreitman, Robert J.
  • Santos, Gimena Dos
  • Dreta, Bárbara
  • Efstathopoulou, María
  • El-Ashwah, Shaimaa
  • Enrico, Alicia
  • Fresa, Alberto
  • Galimberti, Sara
  • Galitzia, Andrea
  • García-Serra, Rocío
  • Gimeno, Eva
  • Labrador, Jorge
  • González-Gascón y Marín, Isabel
  • Gozzetti, Alessandro
  • Guarente, Valerio
  • Guieze, Romain
  • Gogia, Ajay
  • Gupta, Ritu
  • Harrop, Sean
  • Hatzimichael, Eleftheria
  • Herishanu, Yair
  • Hernández-Rivas, José Ángel
  • Lad, Deepesh
  • Inchiappa, Luca
  • Jaksic, Ozren
  • Janssen, Susanne
  • Kalicińska, Elżbieta
  • Kamel, Laribi
  • Karakus, Volkan
  • Kater, Arnon P.
  • Kho, Bonnie
  • Kislova, María
  • Konstantinou, Eliana
  • Levin, Mark-David
  • Koren-Michowitz, Maya
  • Kotsianidis, Ioannis
  • Levy, Ilana
  • Longval, Thomas
  • López-García, Alberto
  • Marquet, Juan
  • Martín-Rodríguez, Lucía
  • Maynadié, Marc
  • Tadmor, Tamar
  • Maslejova, Stanislava
  • Mayor-Bastida, Carlota
  • Mihaljevic, Biljana
  • Milosevic, Ivana
  • Mirás, Fátima
  • Moia, Riccardo
  • Morawska, Marta
  • Murru, Roberta
  • Nath, Uttam Kumar
  • Navarro-Bailón, Almudena
  • Tomic, Kristina
  • Oliveira, Ana C.
  • Olivieri, Jacopo
  • Oscier, David
  • Panovska-Stavridis, Irina
  • Papaioannou, María
  • Papajík, Tomás
  • Kubova, Zuzana
  • Phumphukhieo, Punyarat
  • Pierie, Cheyenne
  • Puiggros, Anna
  • Tse, Eric
  • Rani, Lata
  • Reda, Gianluigi
  • Rigolin, Gian Matteo
  • Ruchlemer, Rosa
  • Daniel de Deus Santos, Marcos
  • Schipani, Mattia
  • Schiwitza, Annett
  • Shen, Yandong
  • Simkovic, Martín
  • Smirnova, Svetlana
  • Vassilakopoulos, Theodoros
  • Abdelrahman Soliman, Dina Sameh
  • Spacek, Martin
  • Visentin, Andrea
  • Vitale, Candida
  • von Tresckow, Julia
  • Vrachiolias, George
  • Vukovic, Vojin
  • Walewska, Renata
  • Al-Shemari, Salem
  • Wasik-Szczepanek, Ewa
  • Xu, Zhenshu
  • Yagci, Munci
  • Yáñez, Lucrecia
  • Yassin, Mohamed
  • Zuchnicka, Jana
  • Angelopoulou, Maria
  • Antic, Darko
  • Biderman, Bella
  • Catherwood, Mark
  • Aurran-Schleinitz, Thérèse
  • Claus, Rainer
  • Coscia, Marta
  • Cuneo, Antonio
  • Demirkan, Fatih
  • Espinet, Blanca
  • Gaidano, Gianluca
  • Kalashnikova, Olga B.
  • Laurenti, Luca
  • Nikitin, Eugene
  • Pangalis, Gerassimos A.
  • Bacchiarri, Francesca
  • Panagiotidis, Panagiotis
  • Popov, Viola María
  • Pospisilova, Sarka
  • Sportoletti, Paolo
  • Stavroyianni, Niki
  • Tam, Constantine S.
  • Trentin, Livio
  • Chatzidimitriou, Anastasia
  • Bosch, Francesc
  • Doubek, Michael
  • Bellido, Mar
  • Ghia, Paolo
  • Stamatopoulos, Kostas
  • Bijou, Fontanet
[Background]: Patients with chronic lymphocytic leukemia (CLL) have a higher risk of developing other malignancies (OMs) compared to the general population. However, the impact of CLL-related risk factors and CLL-directed treatment is still unclear and represents the focus of this work., [Methods]: We conducted a retrospective international multicenter study to assess the incidence of OMs and detect potential risk factors in 19,705 patients with CLL, small lymphocytic lymphoma, or high-count CLL-like monoclonal B-cell lymphocytosis, diagnosed between 2000 and 2016. Data collection took place between October 2020 and March 2022., [Findings]: In 129,254 years of follow-up after CLL diagnosis, 3513 OMs were diagnosed (27.2 OMs/1000 person-years). The most common hematological OMs were Richter transformation, myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Non-melanoma skin (NMSC) and prostate cancers were the most common solid tumors (STs). The only predictor for MDS and AML development was treatment with fludarabine and cyclophosphamide with/without rituximab (FC ± R) (OR = 3.7; 95% CI = 2.79–4.91; p < 0.001). STs were more frequent in males and patients with unmutated immunoglobulin heavy variable genes (OR = 1.77; 95% CI = 1.49–2.11; p < 0.001/OR = 1.89; 95% CI = 1.6–2.24; p < 0.001). CLL-directed treatment was associated with non-melanoma skin and prostate cancers (OR = 1.8; 95% CI = 1.36–2.41; p < 0.001/OR = 2.11; 95% CI = 1.12–3.97; p = 0.021). In contrast, breast cancers were more frequent in untreated patients (OR = 0.17; 95% CI = 0.08–0.33; p < 0.001). Patients with CLL and an OM had inferior overall survival (OS) than those without. AML and MDS conferred the worst OS (p < 0.001)., [Interpretation]: OMs in CLL impact on OS. Treatment for CLL increased the risk for AML/MDS, prostate cancer, and NMSC. FCR was associated with increased risk for AML/MDS., This project was supported in part by AbbVie; EU/EFPIA Innovative Medicines Initiative [2] Joint Undertaking HARMONY grant n° 116026; the Hellenic Precision Medicine Network in Oncology; MH-CZ_AZV_NU23-03-00401; MH CZ DRO (FNBr, 65269705); MH CZ DRO (FNOl, 00098892), program COOPERATIO (research area ONCO), and NPO-NUVR LX22NPO5102., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY study

  • Hernández-Sánchez, Alberto
  • González, Teresa
  • Sobas, Marta
  • Sträng, Eric
  • Castellani, Gastone
  • Abáigar, María
  • Valk, Peter J. M.
  • Villaverde-Ramiro, Ángela
  • Benner, Axel
  • Metzeler, Klaus H.
  • Azibeiro, Raúl
  • Tettero, Jesse M.
  • Martínez-López, Joaquín
  • Pratcorona, Marta
  • Martínez Elicegui, Javier
  • Mills, Ken I.
  • Thiede, Christian
  • Sanz, Guillermo
  • Döhner, Konstanze
  • Heuser, Michael
  • Haferlach, Torsten
  • Turki, Amin T.
  • Reinhardt, Dirk
  • Schulze-Rath, Renate
  • Barbus, Martje
  • Hernández, Jesús M.
  • Huntly, Brian J. P.
  • Ossenkoppele, Gert
  • Döhner, Hartmut
  • Bullinger, Lars
Balanced rearrangements involving the KMT2A gene (KMT2Ar) are recurrent genetic abnormalities in acute myeloid leukemia (AML), but there is lack of consensus regarding the prognostic impact of different fusion partners. Moreover, prognostic implications of gene mutations co-occurring with KMT2Ar are not established. From the HARMONY AML database 205 KMT2Ar adult patients were selected, 185 of whom had mutational information by a panel-based next-generation sequencing analysis. Overall survival (OS) was similar across the different translocations, including t(9;11)(p21.3;q23.3)/KMT2A::MLLT3 (p = 0.756). However, independent prognostic factors for OS in intensively treated patients were age >60 years (HR 2.1, p = 0.001), secondary AML (HR 2.2, p = 0.043), DNMT3A-mut (HR 2.1, p = 0.047) and KRAS-mut (HR 2.0, p = 0.005). In the subset of patients with de novo AML < 60 years, KRAS and TP53 were the prognostically most relevant mutated genes, as patients with a mutation of any of those two genes had a lower complete remission rate (50% vs 86%, p < 0.001) and inferior OS (median 7 vs 30 months, p < 0.001). Allogeneic hematopoietic stem cell transplantation in first complete remission was able to improve OS (p = 0.003). Our study highlights the importance of the mutational patterns in adult KMT2Ar AML and provides new insights into more accurate prognostic stratification of these patients., Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). This study presents results from the AML workgroup in HARMONY. AHS is supported by Contrato Río Hortega CM23/00101 (ISCIII). ATT received additional support by the Deutsche Forschungsgemeinschaft (DFG) grant FU 356/12-1 (ATT). Open Access funding enabled and organized by Projekt DEAL., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN–HARMONY Alliance platform

  • Mosquera Orgueira, Adrián
  • González Pérez, Marta Sonia
  • D'Agostino, Mattia
  • Cairns, David A.
  • Larocca, Alessandra
  • Lahuerta, Juan José
  • Wester, R.
  • Bertsch, Uta
  • Zamagni, Elena
  • Pérez Míguez, Carlos
  • Rojas Martínez, Javier Alberto
  • Mai, Elias K.
  • Crucitti, Davide
  • Salwender, Hans
  • Dall’Olio, Daniele
  • Castellani, Gastone
  • Piñeiro, Manuel
  • Bringhen, Sara
  • Zweegman, Sonja
  • Cavo, Michele
  • Iqbal, Sofía
  • Hernández, Jesús M.
  • Bruno, Benedetto
  • Cook, Gordon
  • Kaiser, Martin F.
  • Goldschmidt, Hartmut
  • Donk, Niels W. C. J. van de
  • Jackson, Graham
  • San Miguel, Jesús F.
  • Boccadoro, Mario
  • Mateos, Maria Victoria
  • Sonneveld, Pieter
Traditional risk stratification in multiple myeloma (MM) relies on clinical and cytogenetic parameters but has limited predictive accuracy. Machine learning (ML) offers a novel approach by leveraging large datasets and complex variable interactions. This study aimed to develop and validate novel ML-driven prognostic scores for newly diagnosed MM (NDMM), with the goal of improving upon existing ones. To this end, we analyzed data from the EMN–HARMONY MM cohort, comprising 14,345 patients, including 10,843 NDMM patients enrolled across 16 clinical trials. Three ML models were developed: (1) a comprehensive model incorporating 20 variables, (2) a reduced model including six key variables (age, hemoglobin, β2-microglobulin, albumin, 1q gain, and 17p deletion), and (3) a cytogenetics-free model. All models were internally validated using out-of-bag cross-validation and externally validated with data from the Myeloma XI trial. Model performance was evaluated using the concordance index (C-index) and time-dependent area under the receiver operating characteristic curve (ROC-AUC). The comprehensive model achieved C-index values of 0.666 (training) and 0.667 (test) for overall survival (OS) and 0.620/0.627 for progression-free survival (PFS). The reduced model maintained accuracy (OS: 0.658/0.657; PFS: 0.608/0.614). The cytogenetics-free model showed C-index values of 0.636/0.643 for OS and 0.600/0.610 for PFS. Incorporating treatment type and best response to first-line treatment further improved performance. The new prognostic models improved over the International Staging System (ISS), Revised International Staging System (R-ISS), and Second Revision of the International Staging System (R2-ISS) and were reproducible in real-world and relapsed/refractory MM, including daratumumab-treated patients. This ML-based risk stratification strategy provides individualized risk predictions, surpassing traditional group-based methods and demonstrating broad applicability across patient subgroups., This work was supported by the HARMONY and HARMONY PLUS projects (IMI2 Joint Undertaking under grant agreements No. 116026 and No. 945406), which receive funding from the European Union's Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance

  • Sobas, Marta
  • Turki, Amin T,
  • Villaverde-Ramiro, Ángela
  • Hernández-Sánchez, Alberto
  • Elicegui, Javier Martinez
  • González, Teresa
  • Azibeiro, Raúl
  • Abáigar, María
  • Tur, Laura
  • Dall'Olio, Daniele
  • Sträng, Eric
  • Tettero, Jesse M.
  • Castellani, Gastone
  • Benner, Axel
  • Döhner, Konstanze
  • Thiede, Christian
  • Metzeler, Klaus H.
  • Haferlach, Torsten
  • Damm, Frederik
  • Ayala, Rosa
  • Martínez-López, Joaquín
  • Mills, Ken I.
  • Sierra, Jorge
  • Lehmann, Sören
  • Porta, Matteo Della
  • Mayer, Jiri
  • Reinhardt, Dirk
  • Medina, Rubén Villoria
  • Schulze-Rath, Renate
  • Barbus, Martje
  • Hernández, Jesús M.
  • Huntly, Brian J. P.
  • Ossenkoppele, Gert
  • Döhner, Hartmut
  • Bullinger, Lars
Since 2017, targeted therapies combined with conventional intensive chemotherapy have started to improve outcomes of patients with acute myeloid leukemia (AML). However, even before these innovations, outcomes with intensive chemotherapy had improved, which has not yet been extensively studied. Thus, we used a large pan-European multicenter dataset of the HARMONY Alliance to evaluate treatment-time dependent outcomes over two decades. In 5,359 AML patients, we compared the impact of intensive induction therapy on outcome over four consecutive 5-year calendar periods from 1997 to 2016. During that time, the 5-year survival of AML patients improved significantly, also across different genetic risk groups. In particular, the 60-day mortality rate dropped from 13.0% to 4.7% over time. The independent effect of calendar periods on outcome was confirmed in multivariate models. Improvements were documented both for patients <60 and ≥60 years old, and in those treated with and without consolidating allogeneic hematopoietic stem cell transplantation (alloHCT). While survival of AML elderly patients remains poor, patients ≥60 years old overall have a 20% survival benefit at 5 years if they receive an alloHCT. While further outcome improvement in intensively treated AML patients will likely be driven by targeted treatment approaches, this pan-European HARMONY dataset can serve as a multicenter comparator for future studies., The Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY (HARMONY) has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under HARMONY Grant Agreement N. 116026. This Joint Undertaking received support from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA. This study presents results from the AML workgroup in HARMONY. ATT received additional support from the Deutsche Forschungsgemeinschaft (DFG) grant FU 356/12-1 (ATT). AHS is supported by Contrato Río Hortega CM23/00101., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

  • Chatzikonstantinou, Thomas
  • Gimeno Vázquez, Eva
  • Puiggros Metje, Anna Maria
  • Espinet Solà, Blanca
  • Stamatopoulos, Kostas
Background: Patients with chronic lymphocytic leukemia (CLL) have a higher risk of developing other malignancies (OMs) compared to the general population. However, the impact of CLL-related risk factors and CLL-directed treatment is still unclear and represents the focus of this work. Methods: We conducted a retrospective international multicenter study to assess the incidence of OMs and detect potential risk factors in 19,705 patients with CLL, small lymphocytic lymphoma, or high-count CLL-like monoclonal B-cell lymphocytosis, diagnosed between 2000 and 2016. Data collection took place between October 2020 and March 2022. Findings: In 129,254 years of follow-up after CLL diagnosis, 3513 OMs were diagnosed (27.2 OMs/1000 person-years). The most common hematological OMs were Richter transformation, myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Non-melanoma skin (NMSC) and prostate cancers were the most common solid tumors (STs).The only predictor for MDS and AML development was treatment with fludarabine and cyclophosphamide with/without rituximab (FC ± R) (OR = 3.7; 95% CI = 2.79-4.91; p < 0.001). STs were more frequent in males and patients with unmutated immunoglobulin heavy variable genes (OR = 1.77; 95% CI = 1.49-2.11; p < 0.001/OR = 1.89; 95% CI = 1.6-2.24; p < 0.001).CLL-directed treatment was associated with non-melanoma skin and prostate cancers (OR = 1.8; 95% CI = 1.36-2.41; p < 0.001/OR = 2.11; 95% CI = 1.12-3.97; p = 0.021). In contrast, breast cancers were more frequent in untreated patients (OR = 0.17; 95% CI = 0.08-0.33; p < 0.001).Patients with CLL and an OM had inferior overall survival (OS) than those without. AML and MDS conferred the worst OS (p < 0.001). Interpretation: OMs in CLL impact on OS. Treatment for CLL increased the risk for AML/MDS, prostate cancer, and NMSC. FCR was associated with increased risk for AML/MDS. Funding: AbbVie, and EU/EFPIAInnovative Medicines Initiative Joint Undertaking HARMONY grant n° 116026., This project was supported in part by AbbVie; EU/EFPIA Innovative Medicines Initiative [2] Joint Undertaking HARMONY grant n° 116026; the Hellenic Precision Medicine Network in Oncology; MH-CZ_AZV_NU23-03-00401; MH CZ DRO (FNBr, 65269705); MH CZ DRO (FNOl, 00098892), program COOPERATIO (research area ONCO), and NPO-NUVR LX22NPO5102. Munci Yagci was provided with study materials.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia

  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • García-Calduch, Olga
  • Ribera Salas, Jordi|||0000-0003-4796-6470
  • Montesinos, Pau|||0000-0002-3275-5593
  • Cano-Ferri, Isabel
  • Martínez Sánchez, Pilar|||0000-0002-7334-140X
  • Esteve Reyner, Jordi|||0000-0002-8056-648X
  • Esteban Corredera, Daniel|||0000-0001-8897-3170
  • García Fortes, María|||0000-0002-0959-9449
  • Alonso Vence, Natalia
  • González Campos, José
  • Bermúdez, Arancha
  • Torrent Catarineu, Anna|||0000-0002-3727-5716
  • Genescà, Eulàlia|||0000-0002-5657-4842
  • Mercadal, Santiago|||0000-0003-4741-7885
  • Martínez-Lopez, Joaquín
  • García-Sanz, Ramón|||0000-0003-4120-2787
Promising results have been shown with the combination of ponatinib and chemotherapy in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). The PONALFIL (Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia) trial combined ponatinib (30 mg/d) with standard induction and consolidation chemotherapy followed by allogeneic hematopoietic stem cell transplant (alloHSCT) in newly diagnosed Ph + ALL patients aged 18 to 60 years. Ponatinib was only given pre-emptively after alloHSCT. Primary end points were hematologic and molecular response before alloHSCT and event-free survival (EFS), including molecular relapse as event. Thirty patients (median age, 49 years; range, 19-59 years) entered the trial. All exhibited hematologic response, and alloHSCT was performed in 26 patients (20 in complete molecular response and 6 in major molecular response). Only 1 patient died (of graft-versus-host disease), and 5 patients exhibited molecular relapse after alloHSCT. No tyrosine kinase inhibitor was given after HSCT in 18 of 26 patients. Twenty-nine patients are alive (median follow-up, 2.1 years; range, 0.2-4.0 years), with 3-year EFS and overall survival (OS) of 70% (95% confidence interval, 51-89) and 96% (95% confidence interval, 89-100), respectively. Comparison of the PONALFIL and the ALLPh08 (Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph [BCR-ABL] Positive; same schedule, using imatinib as the tyrosine kinase inhibitor) trials by propensity score showed significant improvement in OS for patients in PONALFIL (3-year OS, 96% vs 53%; P =.002). The most frequent grade 3 to 4 adverse events were hematologic (42%), infectious (17%), and hepatic (22%), with only one vascular occlusive event. The combination of chemotherapy with ponatinib followed by alloHSCT is well tolerated, with encouraging EFS in adults with newly diagnosed Ph + ALL. Cross-trial comparison suggests improvement vs imatinib (clinicaltrials.gov identifier #NCT02776605).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

  • Sauta, Elisabetta|||0000-0002-7830-988X
  • Robin, Marie
  • Bersanelli, Mateo|||0000-0001-9041-5493
  • Travaglino, Erica
  • Meggendorfer, Manje
  • Zhao, Lin-Pierre|||0000-0001-5035-4470
  • Caballero Berrocal, Juan Carlos
  • Sala, Claudia|||0000-0002-4889-1047
  • Maggioni, Giulia|||0000-0002-8652-4854
  • Bernardi, Massimo|||0000-0002-1334-0851
  • Di Grazia, Carmen
  • Vago, Luca|||0000-0003-4247-3175
  • Rivoli, Giulia
  • Borin, Lorenza
  • D'Amico, Saverio|||0000-0003-1877-8497
  • Tentori, Cristina Astrid
  • Ubezio, Marta|||0000-0003-3862-7119
  • Campagna, Alessia|||0000-0002-8481-759X
  • Russo, Antonio
  • Mannina, Daniele|||0000-0002-1378-6896
  • Lanino, Luca|||0000-0003-2404-8829
  • Chiusolo, Patrizia|||0000-0002-1355-1587
  • Giaccone, Luisa
  • Voso, Maria Teresa|||0000-0002-6164-4761
  • Riva, Maria
  • Oliva, Esther Natalie|||0000-0001-9238-5734
  • Zampini, Matteo|||0000-0002-9952-1142
  • Riva, Elena|||0000-0002-0701-3889
  • Nibourel, Olivier
  • Bicchieri, Marinela|||0000-0001-9674-9304
  • Bolli, Niccolo
  • Rambaldi, Alessandro|||0000-0002-3739-7502
  • Passamonti, Francesco|||0000-0001-8068-5289
  • Savevski, Victor|||0000-0002-3376-8740
  • Santoro, Armando
  • Germing, Ulrich
  • Kordasti, Shahram|||0000-0002-0347-4207
  • Santini, Valeria|||0000-0002-5439-2172
  • Diez-Campelo, María|||0000-0002-1467-6779
  • Sanz, Guillermo|||0000-0002-2767-8191
  • Sole, F.|||0000-0002-3251-2161
  • Kern, Wolfgang|||0000-0002-6452-2874
  • Platzbecker, Uwe|||0000-0003-1863-3239
  • Arenillas, Leonor|||0000-0002-9020-8766
  • Fenaux, Pierre
  • Haferlach, T.|||0000-0003-0196-2837
  • Castellani, Gastone|||0000-0003-4892-925X
  • Della Porta, Matteo Giovanni|||0000-0002-6915-5970
PURPOSEMyelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in which a risk-adapted treatment strategy is needed. Recently, a new clinical-molecular prognostic model, the Molecular International Prognostic Scoring System (IPSS-M) was proposed to improve the prediction of clinical outcome of the currently available tool (Revised International Prognostic Scoring System [IPSS-R]). We aimed to provide an extensive validation of IPSS-M.METHODSA total of 2,876 patients with primary MDS from the GenoMed4All consortium were retrospectively analyzed.RESULTSIPSS-M improved prognostic discrimination across all clinical end points with respect to IPSS-R (concordance was 0.81 v 0.74 for overall survival and 0.89 v 0.76 for leukemia-free survival, respectively). This was true even in those patients without detectable gene mutations. Compared with the IPSS-R based stratification, the IPSS-M risk group changed in 46% of patients (23.6% and 22.4% of subjects were upstaged and downstaged, respectively).In patients treated with hematopoietic stem cell transplantation (HSCT), IPSS-M significantly improved the prediction of the risk of disease relapse and the probability of post-transplantation survival versus IPSS-R (concordance was 0.76 v 0.60 for overall survival and 0.89 v 0.70 for probability of relapse, respectively). In high-risk patients treated with hypomethylating agents (HMA), IPSS-M failed to stratify individual probability of response; response duration and probability of survival were inversely related to IPSS-M risk.Finally, we tested the accuracy in predicting IPSS-M when molecular information was missed and we defined a minimum set of 15 relevant genes associated with high performance of the score.CONCLUSIONIPSS-M improves MDS prognostication and might result in a more effective selection of candidates to HSCT. Additional factors other than gene mutations can be involved in determining HMA sensitivity. The definition of a minimum set of relevant genes may facilitate the clinical implementation of the score.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes, a multicentre, observational cohort study

  • Maggioni, Giulia|||0000-0002-8652-4854
  • Bersanelli, Matteo
  • Travaglino, Erica
  • Alfonso-Piérola, Ana|||0000-0002-2478-5354
  • Kasprzak, Annika
  • Sangerman Montserrat, Arnan
  • Sauta, Elisabetta|||0000-0002-7830-988X
  • Sala, Claudia|||0000-0002-4889-1047
  • Matteuzzi, Tommaso|||0000-0002-1915-9148
  • Meggendorfer, Manja
  • Gnocchi, Matteo
  • Zhao, Lin-Pierre|||0000-0001-5035-4470
  • Tentori, Cristina Astrid
  • Nachtkamp, Kathrin
  • Dall'Olio, Daniele
  • Mosca, Ettore|||0000-0002-3102-5150
  • Ubezio, Marta|||0000-0003-3862-7119
  • Campagna, Alessia|||0000-0002-8481-759X
  • Russo, Antonio
  • Rivoli, Giulia
  • Bernardi, Massimo|||0000-0002-1334-0851
  • Borin, Lorenza
  • Voso, Maria Teresa|||0000-0002-6164-4761
  • Riva, Marta
  • Oliva, Esther
  • Zampini, Matteo|||0000-0002-9952-1142
  • Riva, Elena|||0000-0002-0701-3889
  • Saba, Elena|||0000-0002-8217-5968
  • D'Amico, Saverio|||0000-0003-1877-8497
  • Lanino, Luca|||0000-0003-2404-8829
  • Tinterri, Benedetta
  • Re, Francesca
  • Bicchieri, Marilena
  • Giordano, Laura|||0000-0002-9587-7870
  • Angelotti, Giovanni|||0000-0003-3264-2721
  • Morandini, Pierandrea|||0000-0002-8615-3766
  • Kubasch, Anne Sophie|||0000-0002-0747-4941
  • Passamonti, Francesco|||0000-0001-8068-5289
  • Rambaldi, Alessandro|||0000-0002-3739-7502
  • Savevski, Victor|||0000-0002-3376-8740
  • Santoro, Armando
  • van de Loosdrecht, Arjan A.
  • Brogi, Alice
  • Santini, Valeria|||0000-0002-5439-2172
  • Kordasti, Shahram|||0000-0002-0347-4207
  • Sanz, Guillermo|||0000-0002-2767-8191
  • Sole, F.|||0000-0002-3251-2161
  • Gattermann, Norbert
  • Kern, Wolfgang|||0000-0002-6452-2874
  • Platzbecker, Uwe|||0000-0003-1863-3239
  • Adès, Lionel
  • Fenaux, Pierre
  • Haferlach, T.|||0000-0003-0196-2837
  • Castellani, Gastone|||0000-0003-4892-925X
  • Germing, Ulrich
  • Diez-Campelo, María|||0000-0002-1467-6779
  • Della Porta, Matteo Giovanni|||0000-0002-6915-5970
Background: Sex is a major source of diversity among patients and a sex-informed approach is becoming a new paradigm in precision medicine. We aimed to describe sex diversity in myelodysplastic syndromes in terms of disease genotype, phenotype, and clinical outcome. Moreover, we sought to incorporate sex information into the clinical decision-making process as a fundamental component of patient individuality. Methods: In this multicentre, observational cohort study, we retrospectively analysed 13 284 patients aged 18 years or older with a diagnosis of myelodysplastic syndrome according to 2016 WHO criteria included in the EuroMDS network (n=2025), International Working Group for Prognosis in MDS (IWG-PM; n=2387), the Spanish Group of Myelodysplastic Syndromes registry (GESMD; n=7687), or the Düsseldorf MDS registry (n=1185). Recruitment periods for these cohorts were between 1990 and 2016. The correlation between sex and genomic features was analysed in the EuroMDS cohort and validated in the IWG-PM cohort. The effect of sex on clinical outcome, with overall survival as the main endpoint, was analysed in the EuroMDS population and validated in the other three cohorts. Finally, novel prognostic models incorporating sex and genomic information were built and validated, and compared to the widely used revised International Prognostic Scoring System (IPSS-R). This study is registered with ClinicalTrials.gov, NCT04889729. Findings: The study included 7792 (58·7%) men and 5492 (41·3%) women. 10 906 (82·1%) patients were White, and race was not reported for 2378 (17·9%) patients. Sex biases were observed at the single-gene level with mutations in seven genes enriched in men (ASXL1, SRSF2, and ZRSR2 p<0·0001 in both cohorts; DDX41 not available in the EuroMDS cohort vs p=0·0062 in the IWG-PM cohort; IDH2 p<0·0001 in EuroMDS vs p=0·042 in IWG-PM; TET2 p=0·031 vs p=0·035; U2AF1 p=0·033 vs p<0·0001) and mutations in two genes were enriched in women (DNMT3A p<0·0001 in EuroMDS vs p=0·011 in IWG-PM; TP53 p=0·030 vs p=0·037). Additionally, sex biases were observed in co-mutational pathways of founding genomic lesions (splicing-related genes, predominantly in men, p<0·0001 in both the EuroMDS and IWG-PM cohorts), in DNA methylation (predominantly in men, p=0·046 in EuroMDS vs p<0·0001 in IWG-PM), and TP53 mutational pathways (predominantly in women, p=0·0073 in EuroMDS vs p<0·0001 in IWG-PM). In the retrospective EuroMDS cohort, men had worse median overall survival (81·3 months, 95% CI 70·4-95·0 in men vs 123·5 months, 104·5-127·5 in women; hazard ratio [HR] 1·40, 95% CI 1·26-1·52; p<0·0001). This result was confirmed in the prospective validation cohorts (median overall survival was 54·7 months, 95% CI 52·4-59·1 in men vs 74·4 months, 69·3-81·2 in women; HR 1·30, 95% CI 1·23-1·35; p<0·0001 in the GEMSD MDS registry; 40·0 months, 95% CI 33·4-43·7 in men vs 54·2 months, 38·6-63·8 in women; HR 1·23, 95% CI 1·08-1·36; p<0·0001 in the Dusseldorf MDS registry). We developed new personalised prognostic tools that included sex information (the sex-informed prognostic scoring system and the sex-informed genomic scoring system). Sex maintained independent prognostic power in all prognostic systems; the highest performance was observed in the model that included both sex and genomic information. A five-to-five mapping between the IPSS-R and new score categories resulted in the re-stratification of 871 (43·0%) of 2025 patients from the EuroMDS cohort and 1003 (42·0%) of 2387 patients from the IWG-PM cohort by using the sex-informed prognostic scoring system, and of 1134 (56·0%) patients from the EuroMDS cohort and 1265 (53·0%) patients from the IWG-PM cohort by using the sex-informed genomic scoring system. We created a web portal that enables outcome predictions based on a sex-informed personalised approach. Interpretation: Our results suggest that a sex-informed approach can improve the personalised decision making process in patients with myelodysplastic syndromes and should be considered in the design of clinical trials including low-risk patients. Funding: European Union (Horizon 2020 and Transcan programs), Italian Association for Cancer Research, Italian Ministry of Health, and Italian Ministry of University and Research.